Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Comparison of serum TFPI2 levels between healthy controls and patients with endometrial cancer. The Mann–Whitney U test showed that the serum TFPI2 levels of patients with endometrial cancer were significantly higher than those of healthy controls (median 196.7 pg/mL vs. 83.3 pg/mL). *** indicates p < 0.001. The dotted line indicates 191 pg/mL. TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques: Comparison, MANN-WHITNEY

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Baseline characteristics of 328 patients with endometrial cancer in the TFPI2-positive and TFPI2-negative groups

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques:

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Serum TFPI2 levels of patients with endometrial cancer by histological types and FIGO stages. ( A ) TFPI2 levels were significantly higher in the high-risk group than in the low-risk group (220.8 pg/mL vs. 187.7 pg/mL, p < 0.001). ( B ) TFPI2 levels were significantly higher in stage III and IV than in stage I (stage I, 189.6 pg/mL; stage III, 230.9 pg/mL; stage IV, 312.5 pg/mL). *** indicates p < 0.001 in the Mann–Whitney U test. The dotted line indicates 191 pg/mL. CS, carcinosarcoma; EMG, endometrioid carcinoma grade; FIGO, International Federation of Gynecology and Obstetrics; TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques: MANN-WHITNEY

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Pearson’s correlation analysis between serum TFPI2 and CA125 levels. There was a low correlation between serum TFPI2 and CA125 levels ( r = 0.203, p < 0.001). CA, cancer antigen; TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques:

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Kaplan–Meier curve of preoperative serum TFPI2 levels and 5-year survival. Serum TFPI2 positivity is associated with poor prognosis in patients with endometrial cancer. P-value was calculated using the log-rank test (HR, 8.22; 95% CI, 2.49–27.1; p < 0.001). CI, confidence interval; HR, hazard ratio; TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques:

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Multivariate analysis of prognostic factors for overall survival

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques:

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Microscopic immunohistochemistry images of TFPI2 expression in endometrial cancer tissues. Microscopic images show immunohistochemistry for TFPI2 in ( A ) clear cell carcinoma with intensity 0, ( B ) endometrioid carcinoma grade 3 with intensity 1+, ( C ) clear cell carcinoma with intensity 2+, and ( D ) serous carcinoma with intensity 3+. There were both IHC-positive and IHC-negative cases for all histological types. HE, hematoxylin eosin; IHC, immunohistochemistry; TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques: Immunohistochemistry, Expressing

Journal: BMC Cancer

Article Title: Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study

doi: 10.1186/s12885-024-12827-0

Figure Lengend Snippet: Boxplots of IHC scores by each histological type. The Mann–Whitney U test showed no significant differences in IHC scores among histological types ( p = 0.427). CS, carcinosarcoma; EMG, endometrioid carcinoma grade; IHC, immunohistochemistry; TFPI2, tissue factor pathway inhibitor 2

Article Snippet: Immunohistochemistry (IHC) was performed using the same concentration of mouse monoclonal anti-TFPI2 antibody (sc-48380, diluted 1:200, Santa Cruz Biotechnology, Inc., CA, USA) as the primary antibody to ensure consistency of our experimental approach [ ].

Techniques: MANN-WHITNEY, Immunohistochemistry

Journal: Journal of Extracellular Vesicles

Article Title: Extracellular vesicles originating from melanoma cells promote dysregulation in haematopoiesis as a component of cancer immunoediting

doi: 10.1002/jev2.12471

Figure Lengend Snippet: Effect of angiogenesis inhibitors on bone marrow cells from female C57BL/6N mice. (a) Schematic illustration of ex‐vivo experimental design. (b) Effect of pazopanib (VEGF inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (c) Effect of pioglitazone (osteopontin inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (d) Effect of epicatechin (ADAMTS‐1 inhibitor) on the inhibition of tEVs‐induced bone marrow cell proliferation. (e) Effect of rmTFPI (tissue factor pathway inhibitor) on the inhibition tEVs‐induced bone marrow cell proliferation. The cells were treated either inhibitors alone or with inhibitors in combination with 5e9 tEVs. The data are presented as means (±SD, n = 3). Statistical significance (* p < 0.01, *** p < 0.001, and **** p < 0.0001) between experimental groups was calculated with using one‐way analysis of variance (ANOVA) with each value Tukey's multiple comparisons test.

Article Snippet: The inhibitory effect of pazopanib, a VEGFR inhibitor (SML3076, Sigma‐Aldrich, Germany), pioglitazone, an osteopontin inhibitor (E6910, Sigma‐Aldrich, Germany), epigallocatechin, an ADAMTS‐1 inhibitor (E3768, Sigma‐Aldrich, Germany), and rmTFPI Protein, a recombinant mouse tissue factor pathway inhibitor (2975‐PI, R&D Systems) were evaluated to assess their abilities to prevent the possible impact of tEVs on the hematopoietic.

Techniques: Ex Vivo, Inhibition